BrainStorm Cell Therapeutics' (BCLI) CEO Chaim Lebovits on Q3 2018 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q3 2018 Earnings Conference Call October 29, 2018 8:30 AM ET


Joseph Petroziello – Vice President-Scientific and Corporate Communications

Chaim Lebovits – President and Chief Executive Officer

Eyal Rubin – Executive Vice President and Chief Financial Officer

Ralph Kern – Chief Operating Officer and Chief Medical Officer


David Bautz – Zacks Investment Research

Caroline Palomeque – Maxim Group

Jason Kolbert – H.C. Wainwright


Good day and welcome to the BrainStorm Cell Therapeutics' Third Quarter 2018 Earnings Call. Today's conference is being recorded.

At this time, I would like to turn the conference over to Joseph Petroziello, Vice President of Scientific and Corporate Communications at BrainStorm. Please go ahead.

Joseph Petroziello

Thank you, operator. And thank you everyone for dialing into today's Q3 2018 results call. Earlier today released its financial results for Q3 2018 by means of a press release that could be also accessed on our company website.

Before we get started, I would like to remind listeners that this quarterly call contains numerous statements, descriptions, forecast and projections regarding Brainstorm Cell Therapeutics, its potential future business operations and performance including financial results for the most recent fiscal quarter, statements regarding the market potential for treatment of neurodegenerative disorders such as ALS, the sufficiency of our existing capital resources for continuing operations in 2018 and beyond, the safety and clinical effectiveness of our NurOwn proprietary technology, our clinical trials of NurOwn and its related development programs, and our ability to develop strategic collaborations and partnerships to support our business planning efforts.

Forward-looking statements are subject to numerous risks and uncertainties many of which are beyond our control, including the risks and uncertainties described from time to time in our SEC filings. Our risks in this regard may differ materially from those projected here

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.